A citation-based method for searching scientific literature

Chad A Bousman, Katarina Arandjelovic, Serafino G Mancuso, Harris A Eyre, Boadie W Dunlop. Pharmacogenomics 2019
Times Cited: 59







List of co-cited articles
434 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
John F Greden, Sagar V Parikh, Anthony J Rothschild, Michael E Thase, Boadie W Dunlop, Charles DeBattista, Charles R Conway, Brent P Forester, Francis M Mondimore, Richard C Shelton,[...]. J Psychiatr Res 2019
82
50

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
401
42

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
206
33



Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
Víctor Pérez, Ariana Salavert, Jordi Espadaler, Miquel Tuson, Jerónimo Saiz-Ruiz, Cristina Sáez-Navarro, Julio Bobes, Enrique Baca-García, Eduard Vieta, José M Olivares,[...]. BMC Psychiatry 2017
76
23

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
A John Rush, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz,[...]. Am J Psychiatry 2006
20

Using a pharmacogenomic algorithm to guide the treatment of depression.
D K Hall-Flavin, J G Winner, J D Allen, J J Jordan, R S Nesheim, K A Snyder, M S Drews, L L Eisterhold, J M Biernacka, D A Mrazek. Transl Psychiatry 2012
115
18

Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
Paul Bradley, Michael Shiekh, Vishaal Mehra, Keith Vrbicky, Stacey Layle, Marilyn C Olson, Alejandra Maciel, Ali Cullors, Jorge A Garces, Andrew A Lukowiak. J Psychiatr Res 2018
60
18

Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel.
Chad Bousman, Abdullah Al Maruf, Daniel J Müller. Curr Opin Psychiatry 2019
29
34

Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.
Zane Zeier, Linda L Carpenter, Ned H Kalin, Carolyn I Rodriguez, William M McDonald, Alik S Widge, Charles B Nemeroff. Am J Psychiatry 2018
52
17


Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
576
15

Commercial pharmacogenetic-based decision-support tools in psychiatry.
Chad A Bousman, Malcolm Hopwood. Lancet Psychiatry 2016
64
15

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Marin M Jukić, Tore Haslemo, Espen Molden, Magnus Ingelman-Sundberg. Am J Psychiatry 2018
53
16

Contribution of common genetic variants to antidepressant response.
Katherine E Tansey, Michel Guipponi, Xiaolan Hu, Enrico Domenici, Glyn Lewis, Alain Malafosse, Jens R Wendland, Cathryn M Lewis, Peter McGuffin, Rudolf Uher. Biol Psychiatry 2013
114
13

Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.
Chiara Fabbri, Joseph Zohar, Alessandro Serretti. Prog Neuropsychopharmacol Biol Psychiatry 2018
26
30



Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Daniel K Hall-Flavin, Joel G Winner, Josiah D Allen, Joseph M Carhart, Brian Proctor, Karen A Snyder, Maureen S Drews, Linda L Eisterhold, Jennifer Geske, David A Mrazek. Pharmacogenet Genomics 2013
117
13

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
Sidney H Kennedy, Raymond W Lam, Roger S McIntyre, S Valérie Tourjman, Venkat Bhat, Pierre Blier, Mehrul Hasnain, Fabrice Jollant, Anthony J Levitt, Glenda M MacQueen,[...]. Can J Psychiatry 2016
353
13

Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.
Lindsay S Elliott, John C Henderson, Moni B Neradilek, Nicolas A Moyer, Kristine C Ashcraft, Ranjit K Thirumaran. PLoS One 2017
70
13

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Elizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J Müller, Henry M Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan-Tsong Chen, Bruce C Carleton, Alfred L George,[...]. Clin Pharmacol Ther 2018
96
13

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
900
11

Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists.
Julie-Anne Tanner, Paige E Davies, Nicholas C Voudouris, Anashe Shahmirian, Deanna Herbert, Nicole Braganza, Ana Gugila, Bryan M Dechairo, James L Kennedy. J Psychiatr Res 2018
20
35

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
P C D Bank, K E Caudle, J J Swen, R S Gammal, M Whirl-Carrillo, T E Klein, M V Relling, H-J Guchelaar. Clin Pharmacol Ther 2018
98
11

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Andrea Cipriani, Toshi A Furukawa, Georgia Salanti, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Julian P T Higgins,[...]. Lancet 2018
803
11

A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
Joel G Winner, Joseph M Carhart, C Anthony Altar, Josiah D Allen, Bryan M Dechairo. Discov Med 2013
108
11


Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
Chiara Fabbri, Katherine E Tansey, Roy H Perlis, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery,[...]. Eur Neuropsychopharmacol 2018
25
28

Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Marin M Jukic, Robert L Smith, Tore Haslemo, Espen Molden, Magnus Ingelman-Sundberg. Lancet Psychiatry 2019
37
18

Prediction of CYP2D6 phenotype from genotype across world populations.
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein, J Steven Leeder. Genet Med 2017
211
10


Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
10

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.
Naomi R Wray, Stephan Ripke, Manuel Mattheisen, Maciej Trzaskowski, Enda M Byrne, Abdel Abdellaoui, Mark J Adams, Esben Agerbo, Tracy M Air, Till M F Andlauer,[...]. Nat Genet 2018
865
10


Analytical validation of a psychiatric pharmacogenomic test.
Michael R Jablonski, Nina King, Yongbao Wang, Joel G Winner, Lucas R Watterson, Sandra Gunselman, Bryan M Dechairo. Per Med 2018
18
33

Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
Michael E Thase, Sagar V Parikh, Anthony J Rothschild, Boadie W Dunlop, Charles DeBattista, Charles R Conway, Brent P Forester, Francis M Mondimore, Richard C Shelton, Matthew Macaluso,[...]. J Clin Psychiatry 2019
18
33

The role of depression pharmacogenetic decision support tools in shared decision making.
Katarina Arandjelovic, Harris A Eyre, Eric Lenze, Ajeet B Singh, Michael Berk, Chad Bousman. J Neural Transm (Vienna) 2019
12
50

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Kelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, Jesse J Swen, Cyrine E Haidar, Teri E Klein, Roseann S Gammal, Mary V Relling, Stuart A Scott, Daniel L Hertz,[...]. Clin Transl Sci 2020
127
10



Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.
Kimberly Peterson, Eric Dieperink, Johanna Anderson, Erin Boundy, Lauren Ferguson, Mark Helfand. Psychopharmacology (Berl) 2017
32
15

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings.
Alejandra Maciel, Ali Cullors, Andrew A Lukowiak, Jorge Garces. Neuropsychiatr Dis Treat 2018
21
23

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Brian F Gage, Anne R Bass, Hannah Lin, Scott C Woller, Scott M Stevens, Noor Al-Hammadi, Juan Li, Tomás Rodríguez, J Philip Miller, Gwendolyn A McMillin,[...]. JAMA 2017
123
8

Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.
Joel G Winner, Joseph M Carhart, C Anthony Altar, Seth Goldfarb, Josiah D Allen, Gabriela Lavezzari, Kelly K Parsons, Andrew G Marshak, Susan Garavaglia, Bryan M Dechairo. Curr Med Res Opin 2015
48
10

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.
S G Leckband, J R Kelsoe, H M Dunnenberger, A L George, E Tran, R Berger, D J Müller, M Whirl-Carrillo, K E Caudle, M Pirmohamed. Clin Pharmacol Ther 2013
142
8

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.
Stefano Porcelli, Chiara Fabbri, Alessandro Serretti. Eur Neuropsychopharmacol 2012
198
8

Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection.
Chad A Bousman, Heather Zierhut, Daniel J Müller. Clin Pharmacol Ther 2019
24
20

A rating scale for depression.
M HAMILTON. J Neurol Neurosurg Psychiatry 1960
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.